Endocrine disruptors are compounds that interfere with human hormone systems, causing widespread health problems.
The Endocrine Disruptor Screening Program (EDSP) is a program implemented by the US EPA for the screening of pesticides, chemicals, and environmental contaminants for their potential to affect the estrogen, androgen, and thyroid hormone systems using a two-tiered screening and testing process. Tier 1 comprises a battery of five (5) In-vitro and six (6) In-vivo screening assays that shall identify substances that have the potential to act as the endocrine disruptor screening chemicals.
JRF has taken a lead in validating the assays and geared-up to offer Tier 1 studies with listed advantages
-
Designing the customised programs for assessing possible endocrine disruptive effects, as per the EPA and OECD guidelines.
-
JRF can offer large capacity with high quality state of the art equipment and accommodate multiple compounds simultaneously.
-
JRF excels in delivering the reports within rapid turnaround times with professional project communication and support from our dedicated team of experts.
-
Our Scientists are capable enough to help you prioritise your testing schedule, minimise animal use, as well as customising the report format.
Tier 1 Screening Battery
In Vitro Assays
|
Assay |
Guideline |
Endpoint |
Study Duration |
|
Androgen Receptor Binding |
OPPTS 890.1150 |
Saturation Binding- Estimation of Kd and Bmax, Competitive Binding with methyl trienolone, - IC50, RBA, |
Experiment:15 days
Report: 30 days |
|
Aromatase |
OPPTS 890.1200 |
Measurement of Generated Estrone by Liquid scintillation counting, IC50 |
Experiment: 15 days
Report: 30 days |
|
Estrogen Receptor Binding |
OPPTS 890.1250 |
Saturation Binding- Estimation of Kd and Bmax, Competitive Binding- 3 Consecutive runs, IC50, RBA, |
Experiment: 15 days
Report: 30 days |
|
Estrogen Receptor Transcriptional Activation |
OPPTS 890.1300 |
Quantitative measurement of bioluminescence product (Luminescence signal) by Luminometer |
Experiment: 15 days
Report: 30 days |
|
Steroidogenesis |
OPPTS 890.1550 |
Measurement of the levels of Testosterone and 17β-Estradiol produced by cell line with LC-MS/MS, 17β-Estradiol will be measured after Derivatization with Dansyl Chloride, Cell Viability at end of treatment using Invitrogen’s LIVE/DEAD Viability kit. |
Experiment: 30 days
Report: 30 days |
In Vivo Assay
|
Assay |
Guideline |
Endpoint |
Study Duration |
|
Uterotrophic Assay |
OPPTS 890.1600 |
Organ Weight:
Uterine Weight both “Wet” Weight and “Dry” Weight
Optional Histopathology:
Uterus |
18 Weeks |
|
Hershberger Bioassay |
OPPTS 890.1400 |
Organ Weight:
Ventral Prostate, Seminal Vesicles, Levator Bulbocavernosus Muscle, Cowpers Glands, Paired Epididy¬mides, Paired Testis Weight, Glans Penis
Optional Organ Weight:
Liver, Kidneys, Adrenals
Optional Hormone Analysis:
T3, T4, Testosterone, LH |
18 Weeks |
|
Pubertal Development And Thyroid Function In Intact Juvenile/Peripubertal Male Rats |
OPPTS 890.1500 |
Sexual Maturation:
Daily Assessment of Preputial Separation
Blood Chemistry
Organ Weights:
Seminal Vesicles/Coagulating Glands, Ventral Prostate, Dorsal Prostate Levator Ani Plus Bulbocaver¬nosus Muscle, Epididymis, Testis, Thyroid (Post Fixation), Liver, Kidney, Adrenals, Pituitary
Histopathology:
Epididymis, Testis, Thyroid, Kidney
Hormone Analysis: T3, T4, THS, Testosterone |
24 Weeks |
|
Pubertal Development And Thyroid Function In Intact Juvenile/Peripubertal Female Rats |
OPPTS 890.1450 |
Sexual Maturation:
Daily Assessment of Vaginal Separation
Blood Chemistry
Organ Weights:
Uterus (Blotted), Ovaries, Thyroid (Post Fixation), Liver, Kidney, Pituitary, Adrenals
Histopathology: Uterus, Ovary, Thyroid, Kidney
Hormone Analysis: T3, T4, THS |
24 Weeks |
Services available at following locations: